Hereditary Cancer Risk Genes Frequently Sequenced on Tumor Genomic Profilesa
Ms. Forman has disclosed that she is a scientific advisor for Invitae Corporation and has received consulting fees from Myriad Genetics, Inc. Dr. Hall has disclosed that he receives research support from Myriad Genetics, Inc., Invitae Corporation, and Foundation Medicine, Inc. The remaining authors have have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network
Ms. Green has disclosed that she has no relevant financial relationships.
Deborah J. Moonan, RN, BSN, Director, Continuing Education, has disclosed that she has no relevant financial relationships.
Ann Gianola, MA, Senior Manager, Continuing Education Accreditation & Program Operations, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Senior Manager, Clinical Content, has disclosed that she has no relevant financial relationships.
Susan D. Darlow, PhD, Oncology Scientist/Medical Writer, has disclosed that she has no relevant financial relationships.
ChapmanPBHauschildARobertC. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med2011;364:2507–2516.
LedermannJHarterPGourleyC. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol2014;15:852–861.
RobsonMEBradburyARArunB. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol2015;33:3660–3667.
ForbesSABeareDGunasekaranP. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res2015;43(Database issue):D805–811.
SchwaederleMZhaoMLeeJJ. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol2015;33:3817–3825.
Fontes JardimDLSchwaederleMWeiC. Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval. J Natl Cancer Inst2015;107.
KaczmarJMGustafsonKSWongYN. Tumor genomic profiling (TGP) in metastatic colorectal cancer (CRC): bridging the community and the tertiary cancer center through genomic consultation (GC) [abstract]. J Clin Oncol2016;34(Suppl):Abstract 538.
ACMG Releases Member Survey Results on Secondary Findings and Reinforces Earlier Recommendations in New Policy Statement on Secondary Findings. Available at: http://www.prnewswire.com/news-releases/acmg-releases-member-survey-results-on-secondary-findings-and-reinforces-earlier-recommendations-in-new-policy-statement-on-secondary-findings-28-2689411.html. Accessed November 14 2014.
Schlich-BakkerKJten KroodeHFAusemsMG. A literature review of the psychological impact of genetic testing on breast cancer patients. Patient Educ Couns2006;62:13–20.
HallMJDalyMBRossEA. Germline variants in cancer risk genes detected by NGS-based comprehensive tumor genomic profiling (CGP) [abstract]. J Clin Oncol2015;33(Suppl):Abstract 11084.
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol2003;21:2397–2406.
Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996. J Clin Oncol1996;14:1730–1736; discussion 1737–1740.
RobsonMEStormCDWeitzelJ. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol2010;28:893–901.
CatenacciDVAmicoALNielsenSM. Tumor genome analysis includes germline genome: are we ready for surprises?Int J Cancer2015;136:1559–1567.
EverettJNStoffelEMInnisJW. Spectrum of germline inherited gastrointestinal syndrome variants in unselectd patients enrolled in a tumor-normal sequencing project [abstract]. Presented at the 2015 Collaborative Group of the Americas on Hereditary Colorectal Cancer Annual Meeting; October11–122015; Baltimore MD. Abstract 36.
NSGC Code of Ethics. National Society of Genetic Counselors Web site. Available at: http://nsgc.org/p/cm/ld/fid=12. Accessed April 22 2016.
BolandPMRuthKMatroJM. Genetic counselors' (GC) knowledge, awareness, understanding of clinical next-generation sequencing (NGS) genomic testing. Clin Genet2015;88:565–572.
MeropolNJDalyMBVigHS. Delivery of Internet-based cancer genetic counselling services to patients' homes: a feasibility study. J Telemed Telecare2011;17:36–40.
SchwartzMDValdimarsdottirHBPeshkinBN. Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol2014;32:618–626.
FecteauHVogelKJHansonKMorrill-CorneliusS. The evolution of cancer risk assessment in the era of next generation sequencing. J Genet Couns2014;23:633–639.
BradburyARPatrick-MillerLLongJ. Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genet Med2015;17:485–492.
DohertyJBonadiesDCMatloffET. Testing for hereditary breast cancer: panel or targeted testing? Experience from a clinical cancer genetics practice. J Genet Couns2015;24:683–687.
InnocentJHandorfEMatroJM. Patient interest and willingness-to-pay (WTP) out-of-pocket (OOP) for comprehensive tumor genetic profiling (CGP) [abstract]. J Clin Oncol2015;33(Suppl):Abstract 1545.
GraySWHicks-CourantKLathanCS. Attitudes of patients with cancer about personalized medicine and somatic genetic testing. J Oncol Pract2012;8:329–335.
ScottRJMeldrumCCrooksR. Familial adenomatous polyposis: more evidence for disease diversity and genetic heterogeneity. Gut2001;48:508–514.
GrovesCJSaundersBPSpigelmanADPhillipsRK. Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut2002;50:636–641.
SwiftMMorrellDCromartieE. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet1986;39:573–583.
AoudeLGGartsideMJohanssonP. Prevalence of germline BAP1, CDKN2A, and CDK4 mutations in an Australian population-based sample of cutaneous melanoma cases. Twin Res Hum Genet2015;18:126–133.
AoudeLGVajdicCMKrickerA. Prevalence of germline BAP1 mutation in a population-based sample of uveal melanoma cases. Pigment Cell Melanoma Res2013;26:278–279.
RaiKPilarskiRCebullaCMAbdel-RahmanMH. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet2016;89:285–294.
RuschAZiltenerGNackaertsK. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases. Lung Cancer2015;87:77–79.
RamusSJSongHDicksE. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J Natl Cancer Inst2015;107.
TungNBattelliCAllenB. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer2015;121:25–33.
CouchFJHartSNSharmaP. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol2015;33:304–311.
WalshTCasadeiSLeeMK. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A2011;108:18032–18037.
Kote-JaraiZLeongamornlertDSaundersE. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer2011;105:1230–1234.
SealSThompsonDRenwickA. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet2006;38:1239–1241.
OliveiraCBordinMCGrehanN. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat2002;19:510–517.
EliasonMJLarsonAAFlorellSR. Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol2006;126:660–666.
Eckerle MizeDBishopMResseESluzevichJ. Familial atypical multiple mole melanoma syndrome. In: Riegert-JohnsonDLBoardmanLAHefferonTRobertsM eds. Cancer Syndromes. Bethesda, MD: National Center for Biotechnology Information; 2009.
FriedrichsenDMMaloneKEDoodyDR. Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women. Breast Cancer Res2004;6:R629–635.
WeischerMBojesenSEEllervikC. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol2008;26:542–548.
WangYDaiBYeD. CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis. Int J Clin Exp Med2015;8:15708–15715.
ScheithauerBWLawsERJrKovacsK. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin Diagn Pathol1987;4:205–211.
de WildeRFEdilBHHrubanRHMaitraA. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol2012;9:199–208.
ten BroekeSWBrohetRMTopsCM. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. J Clin Oncol2015;33:319–325.
BellidoFPinedaMAizaG. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med2016;18:325–332.
ChubbDBroderickPFramptonM. Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing. J Clin Oncol2015;33:426–432.
SekharDPoojaSKumarSRajenderS. RAD51 135G>C substitution increases breast cancer risk in an ethnic-specific manner: a meta-analysis on 21,236 cases and 19,407 controls. Sci Rep2015;5:11588.
SongHDicksERamusSJ. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol2015;33:2901–2907.
JanuszewiczANeumannHPLonI. Incidence and clinical relevance of RET proto-oncogene germline mutations in pheochromocytoma patients. J Hypertens2000;18:1019–1023.
NgeowJHealdBRybickiLA. Prevalence of germline PTEN, BMPR1A, SMAD4, STK11, and ENG mutations in patients with moderate-load colorectal polyps. Gastroenterology2013;144:1402–1409.
van LierMGWagnerAMathus-VliegenEM. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol2010;105:1258–1264; author reply 1265.
GonzalezKDNoltnerKABuzinCH. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol2009;27:1250–1256.
NeumannHPBenderBUBergerDP. Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. J Urol1998;160:1248–1254.